Generics price surge looms as Europe seeks drug supply security
Rising input costs and the push for supply chain resilience under the EU Critical Medicines Act will force European generic drug prices higher, presenting a new inflationary hurdle for healthcare payers.
Europe's generic drug sector is bracing for an inflationary shock. The continent's push to secure vulnerable pharmaceutical supply chains will force medicine prices higher.
Generics and biosimilars account for roughly 70% of drugs used in Europe but make up only 10% to 20% of the total drug bill. However, almost all key starting materials for these medicines are imported from China and India. Domestic manufacturing was largely priced out by aggressive cost-cutting from healthcare payers.
Geopolitical tensions and the COVID-19 pandemic exposed the fragility of this model. The EU Critical Medicines Act is the latest regulatory attempt to address these vulnerabilities. However, executives warn that legislation alone cannot fix the structural economic imbalance. "Europe is fantastic at legislating, but it doesn’t always consider all the implications."
Reshoring production remains an unrealistic aspiration without direct economic incentives. Capital deployment requires a demonstrable return, and current margins do not support it. "My board wouldn’t let me deploy that kind of capital if I can’t show a sensible return, and I wouldn’t be in my job for very long."
An inflationary shock is expected over the next six to twelve months as material, fuel, and borrowing costs rise. These increased expenses will inevitably be passed on to customers, marking a structural end to the era of rock-bottom generic pricing. To illustrate how low margins have fallen, penicillin currently sells for less than a Mars bar or a packet of chewing gum.
For healthcare systems across an aging and increasingly poorer continent, the transition from cost-optimized to resilient supply chains will require accepting higher baseline costs. Without an economic environment that rewards long-term capital investment, Europe risks a future where the security of critical drug supplies simply cannot be guaranteed.
